rs10423928 — GIPR

The Paradoxical GIP Receptor Variant: Less Insulin, Leaner Body

Every time you eat, your gut releases a hormone called GIP (glucose-dependent insulinotropic polypeptide)¹¹ GIP (glucose-dependent insulinotropic polypeptide)
GIP is secreted by K-cells of the small intestinal mucosa in response to glucose and fat ingestion; it accounts for roughly half of the incretin effect that amplifies meal-induced insulin secretion that signals your pancreas to release insulin. The GIPR gene encodes the receptor that detects this signal. rs10423928 is a common variant in an intron of GIPR that subtly disrupts how the receptor is assembled from its mRNA, with a paradoxical metabolic outcome: reduced insulin response but a leaner body.

The Mechanism

rs10423928 sits within an intron of GIPR, but its functional impact is mechanistic, not trivial. The A allele shifts the balance of GIPR mRNA splice variants: it reduces the proportion of transcripts that include exon 9, which encodes part of the seven-helix transmembrane domain required for a fully functional, membrane-anchored receptor. In adipose tissue from A-allele carriers²² In adipose tissue from A-allele carriers
Müller et al. Diabetes 2011 — analysis of adipose biopsies from the Botnia and Danish Twin cohorts showed reduced exon-9-containing isoform abundance in A allele carriers, the proportion of functional GIPR on the cell surface is modestly but consistently reduced.

The net result is a blunted incretin response specifically after oral glucose or fat ingestion. When A-allele carriers receive glucose by mouth, the GIP released from the gut cannot fully activate their pancreatic beta-cell GIPR, so insulin secretion falls short. Crucially, when glucose is given intravenously — bypassing the GIP signal entirely — insulin secretion is normal. This confirms the defect is specifically in the GIP-mediated incretin pathway, not in basal beta-cell function.

The same reduced GIPR function in adipose tissue has an unexpected upside: GIP normally promotes fat storage and adipogenesis. With less receptor signaling, A-allele carriers accumulate less adipose tissue, resulting in lower BMI, reduced fat mass, and lower lean body mass.

rs10423928 is in near-perfect linkage disequilibrium (r²≈0.99) with the missense variant rs1800437 (Glu354Gln)³³ rs1800437 (Glu354Gln)
The E354Q change sits in exon 10 of GIPR and reduces receptor signaling by increasing desensitization and downregulation. The two variants are so tightly co-inherited that they functionally represent the same causal signal, operating through both splicing and protein-level mechanisms.

The Evidence

The foundational study was a GWAS meta-analysis by Saxena et al. in Nature Genetics 2010⁴⁴ GWAS meta-analysis by Saxena et al. in Nature Genetics 2010
Saxena R et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nature Genetics 2010 involving 15,234 discovery and up to 30,620 total nondiabetic participants. The A allele was associated with higher 2-hour glucose (beta=0.09 mmol/L per allele, p=2×10⁻¹⁵), lower insulinogenic index (p=1×10⁻¹⁷), and reduced incretin effect (p=4.3×10⁻⁴) in 804 individuals tested with both oral and intravenous glucose challenges.

A follow-up study in 53,730 nondiabetic and 2,731 diabetic subjects⁵⁵ 53,730 nondiabetic and 2,731 diabetic subjects
Müller et al. Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes 2011 confirmed impaired GIP-stimulated insulin secretion and, strikingly, found that A-allele carriers had approximately 2.9 kg lower lean body mass and reduced fat mass — with the BMI-lowering effect nearly completely offsetting the insulin-secretion impairment in terms of net type 2 diabetes risk.

The Malmö Diet and Cancer cohort⁶⁶ Malmö Diet and Cancer cohort
Renström F et al. Genetic variation in the GIPR modifies the association between carbohydrate and fat intake and type 2 diabetes risk. JCEM 2012 (24,840 subjects followed 12 years) revealed a striking gene-diet interaction: AA homozygotes eating a high-fat, low-carbohydrate diet had a 69% lower T2D risk compared to those eating low-fat; TT homozygotes showed 23% lower T2D risk from a high-carbohydrate, low-fat diet. The macronutrient that bypasses impaired GIP-mediated signaling (fat rather than carbohydrate as the main fuel) aligns with the reduced incretin effect in A-allele carriers.

Practical Actions

For A-allele carriers (AT or AA genotypes), the impaired GIP-mediated insulin response means that high-carbohydrate meals are less efficiently handled — the insulin surge that normally dampens post-meal glucose is blunted. Shifting calories toward fat (unsaturated and omega-3 rich) and moderating carbohydrate intake — particularly refined carbohydrates and sugars — aligns with both the mechanistic evidence and the Malmö cohort findings. Monitoring postprandial glucose (particularly the 2-hour mark after meals) provides direct feedback on how this genotype affects meal tolerance.

The variant is also pharmacogenomically relevant: tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor co-agonist that works partly through GIPR. Reduced receptor function from rs10423928 may blunt the GIPR component of tirzepatide's effect, though direct clinical evidence in carriers is not yet published.

Interactions

rs10423928 acts in the incretin pathway alongside GLP-1R variants. The GLP-1R variant rs6923761 (Gly168Ser) affects the parallel incretin arm — GLP-1 signaling — and has been associated with differential responses to GLP-1-based therapies. Carriers of reduced-function variants in both GIPR (rs10423928 A allele) and GLP-1R may have compounded impairment of the overall incretin effect, increasing postprandial glucose excursions. A compound action covering this interaction would be warranted if clinical evidence for combined effects emerges.

Within the GIPR locus, rs10423928 and rs1800437 (E354Q) are in r²≈0.99 LD and co-segregate as a functional haplotype. The related intronic variant rs2302382 has been associated with T2DM risk in Middle Eastern populations and is likely part of the same haplotype block.